Oncotarget

Research Papers:

The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysis

Jianting Long, Shi Fang, Qiangsheng Dai, Xiaolian Liu, Wanshou Zhu _ and Shenming Wang

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:32079-32087. https://doi.org/10.18632/oncotarget.8117

Metrics: PDF 2185 views  |   HTML 2070 views  |   ?  


Abstract

Jianting Long1,*, Shi Fang2,*, Qiangsheng Dai1, Xiaolian Liu3, Wanshou Zhu3, Shenming Wang4

1Department of Medicinal Oncology, The First Affiliated Hospital, SUN Yat-Sen University, Guangzhou 510080, China

2Department of Clinic Nutrition, The First Affiliated Hospital, SUN Yat-Sen University, Guangzhou 510080, China

3Department of Hematology, Gaozhou People’s Hospital, Gaozhou 525200, China

4Department of Vascular Surgery, The First Affiliated Hospital, SUN Yat-Sen University, Guangzhou 510080, China

*These authors are co-first authors

Correspondence to:

Wanshou Zhu, email: zhuwanshou123@126.com

Shenming Wang, email: shenmingwang@hotmail.com

Keywords: acute myeloid leukemia, Wilms’ tumor gene 1, association, meta-analysis

Received: November 18, 2015    Accepted: February 23, 2016    Published: March 16, 2016

ABSTRACT

Although a number of studies suggested that WT1 rs16754 polymorphism might be related to decreased relapse free survival (RFS) and overall survival (OS). The results remain controversial. Published reports were searched in PubMed, EMBASE, and Google Scholar. Twelve publications with 3903 patients had met the inclusion criteria and were subjected to further examination. We found WT1 rs16754 polymorphism was significantly associated with OS in AML (OR = 0.62; 95% CI 0.52 – 0.75; p < 0.00001; I2 = 47%). WT1 rs16754 polymorphism was also significantly associated with RFS in AML (OR = 0.69; 95% CI 0.57 – 0.83; p < 0.001; I2 = 46%). In the subgroup analyses of age, race, and subtype of AML, WT1 rs16754 polymorphism was a independent favorable-risk marker. In conclusion, WT1 rs16754 polymorphism is associated with better survival of AML. It could be used as a cost-effective prognostic biomarker for AML.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8117